NEWTON,
Mass., Sept. 1, 2023 /PRNewswire/ -- Karyopharm
Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical
company pioneering novel cancer therapies, today announced the
appointment of Zhen Su, MD, MBA, to
its Board of Directors, effective August 31,
2023. Dr. Su is currently Chief Executive Officer and a
member of the Board of Directors at Marengo Therapeutics, Inc., a
company pioneering novel T-cell targeting therapeutics to fight
cancer.
"Dr. Su is a physician‐scientist and pharmaceutical industry
leader who brings tremendous experience guiding products through
discovery, clinical development, approval, and global
commercialization," said Richard
Paulson, MBA, Chief Executive Officer of Karyopharm. "His
expertise and counsel will be critical to us as we expand into
different patient populations and potential new indications in
oncology. We are delighted to welcome him to our team and look
forward to the insight he will provide as part of our Board of
Directors."
"I am pleased to join the Board of Karyopharm at this exciting
time in the company's next phase of growth," said Dr. Su. "I look
forward to actively engaging with my fellow Board members and the
Karyopharm leadership team to advance its core programs and deliver
for patients in need of new cancer treatment options."
"Dr. Su is a passionate leader focused on delivering medicines
through all phases of the clinical development lifecycle," said
Barry Greene, Lead Independent
Director of the Karyopharm Board. "We are thrilled to welcome such
a strong strategic advisor and industry leader to our Board of
Directors."
Prior to joining Marengo, Dr.
Su served as SVP, Global Head of Oncology Business Franchise,
including US Head of the Oncology Business Unit, at Merck KGaA.
Prior to that, he served as Chief Medical Officer at EMD Serono and
headed leadership functions at Sanofi's Oncology Division and
GlaxoSmithKline. Before his industry career, Dr. Su served on the
faculty of Duke University Medical
School where he led early oncology clinical studies focusing on
mRNA-based and cell-based immunotherapy and then at the
University of Florida where he was the
director of the Cell and Gene Therapy program. He received his
Doctor of Medicine from Technical University of Dresden in Germany and his MBA from the University of Toronto in Canada.
About XPOVIO® (selinexor)
XPOVIO is a
first-in-class, oral exportin 1 (XPO1) inhibitor and the first of
Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds
to be approved for the treatment of cancer. XPOVIO functions by
selectively binding to and inhibiting the nuclear export protein
XPO1. XPOVIO is approved in the U.S. and marketed by Karyopharm in
multiple oncology indications, including: (i) in combination with
Velcade® (bortezomib) and dexamethasone (XVd) in
patients with multiple myeloma after at least one prior therapy;
(ii) in combination with dexamethasone in patients with heavily
pre-treated multiple myeloma; and (iii) in patients with diffuse
large B-cell lymphoma (DLBCL), including DLBCL arising from
follicular lymphoma, after at least two lines of systemic therapy.
XPOVIO (also known as NEXPOVIO® in certain countries)
has received regulatory approvals in various indications in a
growing number of ex-U.S. territories and countries, including but
not limited to the European Union, the United Kingdom, China, South
Korea, Canada, Israel and Taiwan. XPOVIO and NEXPOVIO is marketed by
Karyopharm's partners, Antengene, Menarini, Neopharm and FORUS, in
China, South Korea, Singapore, Australia, Hong
Kong, Germany, Austria, Israel and Canada.
Please refer to the local Prescribing Information for full
details.
Selinexor is also being investigated in several other mid- and
late-stage clinical trials across multiple high unmet need cancer
indications, including in endometrial cancer and myelofibrosis.
For more information about Karyopharm's products or clinical
trials, please contact the Medical Information department at:
Tel: +1 (888) 209-9326
Email: medicalinformation@karyopharm.com
About Karyopharm Therapeutics
Karyopharm Therapeutics
Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company
pioneering novel cancer therapies. Since its founding, Karyopharm
has been an industry leader in oral Selective Inhibitor of Nuclear
Export (SINE) compound technology, which was developed to address a
fundamental mechanism of oncogenesis: nuclear export dysregulation.
Karyopharm's lead SINE compound and first-in-class, oral exportin 1
(XPO1) inhibitor, XPOVIO® (selinexor), is approved in
the U.S. and marketed by the Company in three oncology indications
and has received regulatory approvals in various indications in a
growing number of ex-U.S. territories and countries, including
Europe and the United Kingdom (as NEXPOVIO®) and
China. Karyopharm has a focused
pipeline targeting multiple high unmet need cancer indications,
including in multiple myeloma, endometrial cancer, myelodysplastic
neoplasms and myelofibrosis. For more information about our people,
science and pipeline, please visit www.karyopharm.com, and follow
us on Twitter at @Karyopharm and LinkedIn.
Forward-Looking Statements
This press release contains
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements include those regarding the ability of selinexor to
treat patients with endometrial cancer; and expectations related to
the clinical development of selinexor and potential regulatory
submissions of selinexor. Such statements are subject to numerous
important factors, risks and uncertainties, many of which are
beyond Karyopharm's control, that may cause actual events or
results to differ materially from Karyopharm's current
expectations. For example, there can be no guarantee that
Karyopharm will successfully commercialize XPOVIO or that any of
Karyopharm's drug candidates, including selinexor and eltanexor,
will successfully complete necessary clinical development phases or
that development of any of Karyopharm's drug candidates will
continue. Further, there can be no guarantee that any positive
developments in the development or commercialization of
Karyopharm's drug candidate portfolio will result in stock price
appreciation. Management's expectations and, therefore, any
forward-looking statements in this press release could also be
affected by risks and uncertainties relating to a number of other
factors, including the following: the adoption of XPOVIO in the
commercial marketplace, the timing and costs involved in
commercializing XPOVIO or any of Karyopharm's drug candidates that
receive regulatory approval; the ability to obtain and retain
regulatory approval of XPOVIO or any of Karyopharm's drug
candidates that receive regulatory approval; Karyopharm's results
of clinical trials and preclinical studies, including subsequent
analysis of existing data and new data received from ongoing and
future studies; the content and timing of decisions made by the
U.S. Food and Drug Administration and other regulatory authorities,
investigational review boards at clinical trial sites and
publication review bodies, including with respect to the need for
additional clinical studies; the ability of Karyopharm or its third
party collaborators or successors in interest to fully perform
their respective obligations under the applicable agreement and the
potential future financial implications of such agreement;
Karyopharm's ability to enroll patients in its clinical trials;
unplanned cash requirements and expenditures; development or
regulatory approval of drug candidates by Karyopharm's competitors
for products or product candidates in which Karyopharm is currently
commercializing or developing; the direct or indirect impact of the
COVID-19 pandemic or any future pandemic on Karyopharm's business,
results of operations and financial condition; and Karyopharm's
ability to obtain, maintain and enforce patent and other
intellectual property protection for any of its products or product
candidates. These and other risks are described under the caption
"Risk Factors" in Karyopharm's Quarterly Report on Form 10-Q for
the quarter ended March 31, 2023,
which was filed with the Securities and Exchange Commission (SEC)
on May 4, 2023, and in other filings
that Karyopharm may make with the SEC in the future. Any
forward-looking statements contained in this press release speak
only as of the date hereof, and, except as required by law,
Karyopharm expressly disclaims any obligation to update any
forward-looking statements, whether as a result of new information,
future events or otherwise.
XPOVIO® and NEXPOVIO® are registered
trademarks of Karyopharm Therapeutics Inc. Any other trademarks
referred to in this release are the property of their respective
owners.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/karyopharm-appoints-zhen-su-md-mba-to-its-board-of-directors-301915458.html
SOURCE Karyopharm Therapeutics Inc.